Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Stanford inventors develop a machine learning algorithm that accurately classifies patients suffering from an aggressive cancer, pancreatic ductal adenocarcinoma (PDAC), into prognostic groups that can predict differences in patient survival times.